New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:40 EDTCELG, HART, ATHX, CYTX, NBS, CAPR, PBMD, FATE, BLUEAlliance for Regenerative Medicine to hold a conference
2nd Annual Regen Med Investor Day is being held in New York on March 26 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
News For BLUE;FATE;PBMD;CYTX;HART;CAPR;ATHX;CELG;NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 21, 2015
10:12 EDTBLUEOptions with decreasing implied volatility
Subscribe for More Information
08:44 EDTBLUEbluebird data suggest patient 'well' on way to cure, says Piper Jaffray
Subscribe for More Information
08:08 EDTCELGAgios Pharmaceuticals to present data at 20th Congress of EHA
Subscribe for More Information
07:48 EDTBLUEbluebird bio up 12% after presenting updated LentiGlobin clinical data
Subscribe for More Information
07:18 EDTBLUEbluebird bio to present LentiGlobin clinical data at EHA congress
bluebird bio announced that data from the ongoing Phase 1/2 HGB-205 study of LentiGlobin BB305 Drug Product will be presented in an oral presentation on June 13 at the 20th Congress of the European Hematology Association, or EHA, in Vienna, Austria. “The early data included in our abstract provide further validation for our approach and important insights into the safety and mechanism of action of LentiGlobin in both beta-thalassemia and sickle cell disease,” said David Davidson, chief medical officer, bluebird bio. “As noted in the abstract, we are pleased to report that the two patients with beta-thalassemia major, on whom we first reported last year at EHA, remained transfusion independent at 14 and 11 months post-transplant. In addition, it is very encouraging that the patient with sickle cell disease is increasing production of HbAT87Q, which has anti-sickling properties, and has not had a post-treatment hospitalization for a sickle cell disease-related event. At EHA we will present further follow up data on all three subjects.”
06:18 EDTFATEFate Therapeutics 6M share Secondary priced at $5.00
Leerink and BMO Capital acted as joint book running managers for the offering.
May 20, 2015
07:10 EDTBLUEPiper Jaffray to hold a symposium
Subscribe for More Information
May 19, 2015
15:13 EDTBLUEbluebird bio June volatility elevated as shares near record high
Subscribe for More Information
12:54 EDTBLUEbluebird bio price target raised to $214 from $154 at BofA/Merrill
BofA/Merrill raised its price target for bluebird bio to $214 after the company this morning announced its regulatory strategy for LentiGlobin BB305 in beta-thalassemia major. It keeps a Buy rating on the name. Wedbush just raised its price target for bluebird shares to $222.
12:51 EDTBLUEbluebird bio price target raised to $222 from $146 at Wedbush
Subscribe for More Information
10:51 EDTBLUEbluebird bio advances as LentiGlobin seen moving faster than expected
The shares of drug developer bluebird bio (BLUE) are surging after the company announced that its LentiGlobin BB305 drug could be granted accelerated approvals in both the U.S. and Europe as a treatment for beta-thalassemia major. In notes to investors earlier today, JPMorgan and Piper were upbeat on the outlook for the drug's development to progress faster than was previously expected. WHAT'S NEW: After meeting with European and U.S. drug regulators, bluebird bio announced that it would participate in the EU's Adaptive Pathways pilot program. The program was launched by the EU in an effort to provide medicine to patients more quickly, the company stated. bluebird bio said that it now believes that it will be able to seek conditional EU approval of LentoGlobin as a treatment for beta-thalassemia major. Following its meeting with the FDA, bluebird said that data for upcoming clinical trials could enable the company to file an application for FDA approval of LentiGlobin. The company added that it had made agreements with the FDA on the general design of two of its upcoming trials. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer wrote that Blubird seems poised to file for EU approval of LentiGlobin much sooner than anticipated, since EU regulators have indicated that they will enable the company to apply for approval on the basis of only two clinical studies, The FDA is also moving more quickly than Schimmer previously anticipated, the analyst stated. Schimmer said he had previously believed that LentiGlobin would be launched in 2020, but he now thinks the drug could be approved as early as 2017 in the EU and 2018-2019 in the U.S. The analyst kept an Overweight rating on the stock. Similarly, JPMorgan analyst Cory Kasimov wrote that LentiGlobin could be approved before his 2019 estimate, particularly in the EU, where the regulator is not requiring any new trials. LentiGlobin's outlook as a beta-thalassemia major treatment has become more certain as a result of the news, according to the analyst, who continued to recommend buying the shares of bluebird bio. PRICE ACTION: In mid-morning trading, bluebird rose 5.4% to $164.85.
08:57 EDTBLUEPiper sees upside to LentiGlobin launch expectations
Piper Jaffray sees upside potential to its expectation that LentiGlobin will launch in 2020 after the bluebird bio this morning provided a regulatory update. Piper believes approval in Europe for treatment of beta-thal major could come as much as three years earlier than expected while approval in the U.S. is likely to be ahead of expectations as well. The firm reiterates an Overweight rating on bluebird with a $186 price target.
08:21 EDTBLUEbluebird bio approval may come sooner than expected, says JPMorgan
JPMorgan analyst Cory Kasimov reiterates an Overweight rating on bluebird bio after the company announced this morning regulatory plans for LentiGlobin in B-thalassemia in the U.S. and Europe. Kasimov says approval could come earlier than the firm's current 2019 estimate with bluebird seeking accelerated approval in both geographies. The analyst recommends remaining a buyer of the stock ahead of the B-thalassemia data in June. Shares of the clinical-stage biotechnology company are up $5.60 to $162 in pre-market trading.
08:17 EDTCELGCelgene says patients experienced clinical remission in Phase II GED-0301 trial
Subscribe for More Information
06:05 EDTBLUEbluebird bio discusses potential approval pathways for LentiGlobin BB305
Subscribe for More Information
May 18, 2015
16:10 EDTFATEFate Therapeutics files to sell 6M shares of common stock
Fate Therapeutics intends to use the net proceeds from the offering for clinical development and research activities, working capital and other general corporate purposes. Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Wedbush PacGrow and H.C. Wainwright & Co., LLC are acting as co-managers
08:44 EDTCELGCelgene data positive, says SunTrust
SunTrust believes that data presented for Celgene's GED-0301 in Crohn's indicated that the drug is effective irrespective of baseline disease severity and CRP levels.Consequently, the firm thinks the data addressed questions raised in an NEJM editorial about the drug. It keeps a $141 price target and Buy rating on the shares.
07:31 EDTCELGCelgene, Acceleron granted fast track designations for luspatercept
Subscribe for More Information
May 14, 2015
11:11 EDTCELGAnalysts divided on significance of Celgene blood cancer drug data
Subscribe for More Information
06:57 EDTPBMDPrima BioMed announces A$15M investment from Ridgeback
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use